News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Deals
Novartis Corporation Says Buys Intercell AG Encephalitis Drug
June 13, 2006
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
ZURICH, June 13 (Reuters) - Swiss drugmaker Novartis has bought the rights to market IC51, a late-stage drug for the prevention of Japanese Encephalitis virus infections from Austrian biotech firm Intercell .
Twitter
LinkedIn
Facebook
Email
Print
Mergers & acquisitions
Europe
MORE ON THIS TOPIC
Collaboration
Lilly Fronts $100M for CSL’s IL-6 Blocker to Bolster I&I, Cardiovascular Pipeline
February 18, 2026
·
2 min read
·
Tristan Manalac
Rare diseases
BioMarin Bet on Amicus To Ease Voxzogo’s Decline. Will It Work?
February 12, 2026
·
4 min read
·
Dan Samorodnitsky
MASH
Madrigal Dives Further Into MASH With up to $4.4B siRNA Deal With Chinese Biotech
February 11, 2026
·
2 min read
·
Tristan Manalac
Artificial intelligence
AI Is Changing Pharma’s Bottom Line Now—But Not Through Splashy Drug Discovery
February 11, 2026
·
8 min read
·
Annalee Armstrong
